This Plain Language Summary of Publication article (PLSP) from Future Cardiology summarised the ATTRibute-CM study, which tested how effectively acoramidis treats transthyretin amyloid cardiomyopathy (ATTR-CM), a heart disease where misfolded proteins accumulate in the heart muscle, causing wall thickening and reduced pumping ability that leads to symptoms like shortness of breath, leg swelling, and irregular heartbeat.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM)’ and was published in ClinicalTrials.gov.

Visit the National Library of Medicine using the link to read the original article.